Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Two triphasic oral contraceptives containing gestodene (GES) (a new progestogen) and levonorgestrel (LNG) were compared with respect to contraceptive effect, cycle control, acceptability and side effects. The serum concentrations of ingested hormones were measured together with ovarian, pituitary, and some adrenal hormones, as well as sex hormone binding globulin (SHBG). The contraceptive effect and cycle control were good with both preparations, and there were only a few minor side effects. SHBG was elevated 2-fold in the LNG group and 3-fold in the GES group. The GES concentration in serum varied more than the LNG concentration, but with correction for variations in SHBG binding, less variability in actual GES and LNG concentrations was seen. Serum levels of FSH, LH, estradiol and progesterone were all depressed with both preparations. The depression was more marked in the GES group, despite lower progestogen ingestion and similar serum concentrations. Equal decreases were found in testosterone, androstenedione and dehydroepiandrosterone sulfate (DHEA-S) with both preparations.
 ...
PMID:Clinical and hormonal effects of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene. 213 74

Twelve patients with symptomatic uterine fibroid were treated with Goserelin acetate, a depot Gn-RH analogue administered s.c. in a dosage of 3.6 mg every 28 days for a 6 month period. Mean age of the patients was 39 (26-47). A menopausal-like state, evidenced by hot flushes, depression, vaginal dryness, hysteroscopic endometrial atrophy, and hormonal values (FSH, LH, E2), was seen in all patients. After only two months of treatment, a significant reduction was noted in the size of the fibroid, being even greater than that in the following four months. Only one patient in the series underwent surgery. General tolerability of the drug was optimal. These data suggest the efficiency of this type of treatment in obtaining a significant reduction of fibroid volume as well as subjective symptomatology. The cost-benefit ratio is optimal, allowing postponement of surgery and the possibility of vaginal, as opposed to abdominal, hysterectomy and affronting problems of anaesthesiology and post-operative recovery for patients "at risk".
 ...
PMID:Use of GnRH depot analogue in the treatment of uterine fibroids. 215 Jul 37

The onset of cessation of oestrous cyclicity and associated organ and hormonal changes were compared in random-bred (RB) and inbred (IB) female Syrian hamsters kept either under short days (8 h light:16 h darkness; 8L:16D) or long days (14L:10D) and given daily afternoon injections of 25 micrograms melatonin. In response to short-day treatment, 100% of the IB hamsters exhibited vaginal acyclicity within 35 days; by comparison, none of the RB animals were acyclic at this time. The IB hamsters also exhibited other changes associated with exposure to short days, including increased body weight, enlarged ovaries, regressed uteri, elevated pituitary concentrations of FSH, and depressed pituitary and plasma concentrations of prolactin. At this time, only the pituitary FSH levels were increased in the RB animals kept under the same short-day conditions. In a second experiment, RB and IB female Syrian hamsters were maintained under long days (14L:10D) and the rate of reproductive regression in response to daily afternoon injections of melatonin was compared. After 8 weeks of melatonin injections, 80% of the IB females were anoestrous, while all RB hamsters were still exhibiting 4-day oestrous cycles. Other changes associated with melatonin administration in the IB females included a marked drop in uterine weight and a depression in pituitary and plasma prolactin levels. The RB hamsters, although they were all still cyclic after 8 weeks, had increased body and ovarian weights, increased pituitary concentrations of FSH, and lower pituitary and plasma prolactin levels.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Rate of reproductive involution following either exposure to short days or daily administration of melatonin is faster in inbred than in random-bred female Syrian hamsters. 249 86

Because the secretion of gonadotrophic hormones is disturbed in some depressive states, it has been hypothesized that gonadotropin-releasing hormone (GnRH) has antidepressant properties in humans, but no clear information has emerged from clinical trials. The lack of experimental psychopharmacological data prompted us to investigate the effects of GnRH on the 'learned helplessness' behavioral model of depression in rats. GnRH was injected i.p. at doses of 0.06, 0.25, 0.50, 1 and 2 mg/kg per day. GnRH significantly reduced the number of escape failures at doses of 1 mg/kg per day or higher during the first shuttle-box session and at doses of 0.25 mg/kg per day onwards during the third shuttle-box session. These antidepressant-like effects of GnRH were similar to those observed with the tricyclic antidepressants imipramine (32 mg/kg per day) or clomipramine (32 mg/kg per day) in the same model. Moreover, while the induction of learned helplessness behaviour resulted in a fall in the plasma levels of FSH and LH, normal values of these hormones could be restored by a behaviorally effective GnRH regimen. From these data it can be suggested that GnRH exhibits an interesting antidepressant-like activity in rats.
 ...
PMID:Gonadotropin-releasing hormone (GnRH) as antidepressant: a psychopharmacological animal study. 249 22

The object of this study was to compare the effects of short photoperiod (SP) and melatonin (MEL) treatment on the reproductive axis in ovariectomized LSH/SsLak hamsters. Animals acclimatized in long photoperiods (LP) (14L:10D) and showing regular estrous cycles were ovariectomized. Half of the operated hamsters received Silastic capsules containing 17-beta estradiol (E2). On the following day the animals were further subdivided into three groups: the animals in one group received daily afternoon injects of melatonin (MEL), those in a second group were given the vehicle, and animals in the third group were transferred from LP to SP (8L:16D). All animals were killed after 30 days. In hamsters without E2 replacement, MEL or SP exposure significantly suppressed serum and pituitary FSH levels, although MEL was more effective in this regard. On the other hand, SP exposure did not change serum FSH levels in animals with E2 implants, whereas MEL effectively suppressed them. SP or MEL reduced serum LH levels to a similar extent in the absence of E2 replacement, yet in animals with E2 implants only MEL significantly lowered LH levels below LP E2-treated controls. This was in contrast to effects on the pituitary where both treatments were equally effective in the depression of LH content. Serum PRL levels were similarly suppressed by MEL or SP exposure in E2-treated hamsters. On the other hand, pituitary PRL levels were not affected by either treatment in animals with E2-containing capsules, whereas SP or MEL treatment both significantly depressed pituitary PRL contents in hamsters without E2 replacement. SP treatment lowered MBH LHRH contents in animals with E2-containing capsules; no other significant changes in hypothalamic LHRH were noted. The data suggest that daily treatment with 25 micrograms of MEL is generally more effective in the suppression of gonadotropin levels than SP exposure. It is suspected that the mode of administration of MEL, and its quantity, may interact with estrogen differently than SP in the induction of physiological changes and regulation of the LHRH system.
 ...
PMID:Comparison of the effects of short photoperiod exposure and melatonin treatment in ovariectomized LSH/SsLaK hamsters. 250 75

Hormonal and clinical evaluation was performed in eleven females with diagnosis of pseudocyesis. Plasma levels of pituitary gonadotropins (FSH-LH), progesterone, estradiol and thyroid hormones (T3, T4, TSH) under basal conditions were measured through radioimmunoassay. Diagnosis of pseudocyesis was made according to the following criteria: a) secondary amenorrhea (greater than 12 weeks); b) two or more symptoms of gestation; c) conviction of being pregnant; d) negative HCG or pelvic ultrasound study. The circulation levels of gonadotropins were within normal limits. Progesterone exhibited a ovulatory pattern and thyroid hormones were normal for every instance. Once case had slight hyperprolactinemia (26.0 ng/ml) with impaired gonadotropin production and ovulatory progesterone. All patients had galactorrhea. The psychological study disclosed a tendency toward depression. Our findings partially confirmed previous observations, differing basically on that we observed normal hormonal trend.
 ...
PMID:[Pseudocyesis: clinical and hormonal evaluation]. 251 25

The hypothesis that increased estradiol production may be the cause of impaired spermatogenesis in infertile men with idiopathic oligozoospermia was tested by administering the aromatase inhibitor, testolactone, and by assessing its effects on sperm output and fertility. Our study was a randomized, placebo-controlled double-blind crossover trial. Subjects (n = 25) with infertility due to unexplained oligozoospermia were given testolactone (2 g/day) or placebo for 8 months followed by crossover to the other treatment for an additional 8 months. Total estradiol and testosterone levels during testolactone exposure did not change from basal and placebo values. However, sex hormone-binding globulin binding capacity consistently decreased (30%, p less than 0.01) and free testosterone levels increased (36%, p less than 0.01). Free estradiol values increased but not significantly. Additionally, LH and FSH serum levels increased by 15% and 20%, respectively (p less than 0.05), and 17 alpha-hydroxyprogesterone values increased by 90% (p less than 0.05) during drug administration. Sperm output and semen quality remained unchanged during either testolactone or placebo treatment, and no pregnancies occurred during the 16-month study. These data suggest that chronic administration of testolactone at this dose fails to maintain aromatase inhibition despite depression of 17,20-desmolase activity with elevated 17 alpha-hydroxyprogesterone and depressed SHBG binding capacity with elevation of free testosterone. Testolactone is not efficacious in the treatment of idiopathic oligozoospermic infertility.
 ...
PMID:Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover. 266

A phase II study with cyproterone acetate (CPA) was done as the primary treatment in female breast cancer patients. Twenty-three patients, mean age 64 years, range 52-75 years, were entered and treated with CPA 400 mg daily. Twenty patients were evaluable and responses were sparse. There was one partial and one complete remission, 17 patients were stable and one patient progressed within 3 months. Side-effects were frequent: five patients complained of nausea, three had severe weight loss, one suffered from depression and seven showed disturbed liver function tests. Six patients had to stop treatment for side-effects, while two other patients were taken off treatment because they developed an acute necrotizing hepatitis. The hepatitis recovered after drug withdrawal in both patients. The serum levels of CPA, cortisol, androstenedione, DHAS, LH, FSH and prolactin were measured during CPA treatment. The levels of cortisol and androstenedione did not change, while LH, FSH and DHAS were suppressed. The DHAS showed an inverse relation to serum CPA concentrations. The prolactin levels rose uniformly. The therapeutic effect of CPA in postmenopausal patients with advanced breast cancer is disappointing, and inferior to that of other progestins. Side-effects are frequent, possibly as a result of the high dosage used in this study. The hormonal changes are different from those of other progestins, which may explain the different efficacies.
 ...
PMID:Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer. 296 61

Cellular ATP levels were measured with the luceferin-luciferase enzyme method in incubated preovulatory granulosa cells in vitro from PMSG-treated immature rats. The ATP levels were depressed by both FSH and LH, FSH being the more effective. Adenosine enhanced the ATP levels about 3-fold, but the depressive effects of gonadotropins could not be overcome by the addition of adenosine. Uptake of adenosine in granulosa cells followed Michaelis-Menten kinetics, with a Km of 15.9 +/- 3.6 microM and a maximum velocity of 1.6 +/- 0.1 pmol/min X 10(5) cells. The half-time for uptake of adenosine was about 40 min. The maximal uptake of adenosine was lowered from 48 +/- 5 to 30 +/- 1 pmol/10(5) cells by FSH treatment of the cells. The basal secretions of cAMP and progesterone from the granulosa cells were slightly but significantly enhanced by adenosine alone. Adenosine markedly enhanced FSH-stimulated cAMP secretion, but not progesterone secretion. A nonmetabolizable adenosine analog, 2-chloro-adenosine, did not affect the ATP levels or the secretion of cAMP from granulosa cells. This study confirms previous observations that adenosine can increase ATP levels and amplify the response to gonadotropins in gonadal cells. A novel finding is that the levels of ATP in granulosa cells are markedly depressed by gonadotropins. It is speculated that this depression of ATP may be a factor in the metabolic control of granulosa cells.
 ...
PMID:Gonadotropin depression of adenosine triphosphate levels and interaction with adenosine in rat granulosa cells. 300 59

The effect of adenohypophysial hormones on rat pineal melatonin content and release was examined in vitro. Medium concentration of radioimmunoassayable melatonin decreased after a 6 h exposure to 1-100 ng/ml FSH; pineal levels of melatonin were only decreased by 100 ng/ml FSH. LH (1-100 ng/ml) augmented significantly medium melatonin concentration, tissue levels being increased at 10 ng/ml LH. Parallel increases of explant and medium melatonin content were found after exposure to 1-100 ng/ml TSH. At the smallest concentration employed (1 ng/ml) prolactin increased melatonin content and release while at 100 ng/ml a significant depression of both parameters was found. Growth hormone (1-10 ng/ml) augmented melatonin levels in medium but failed to modify them at 100 ng/ml, although at this concentration tissue melatonin levels increased. ACTH did not modify pineal melatonin synthesis in vitro.
 ...
PMID:In vitro effects of adenohypophysial hormones on rat pineal melatonin content and release. 303 98


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>